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Summary
Background & Aims: The aims were to review the diagnosis, testing and presentation of acute 
hepatitis C (HCV) in patients initially diagnosed to have drug-induced liver injury (DILI) enrolled 
in the US DILI Network.
Methods: All patients with suspected DILI underwent testing for competing causes of liver 
injury and returned for 6-month follow-up. Causality was adjudicated by consensus expert 
opinion.
Results: Between 2004–2016, 1518 patients were enrolled and adjudicated and underwent 6 
months of follow up. Initial locally acquired anti-HCV results were available in 1457 (96%), but 
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HCV RNA in only 795 (52%). Stored sera were available for repeat testing, so that results were 
available on all 1518 patients (1457 for anti-HCV and 1482 for HCV RNA). 104 subjects (6.9%) 
had evidence of HCV infection- 10 positive for HCV RNA alone, 16 for anti-HCV alone and 78 
for both. All 104 HCV-positive cases were reviewed and 23 cases were adjudicated as acute HCV. 
All presented with acute hepatocellular injury with median ALT 1448 U/L, alkaline phosphatase 
232 U/L and total bilirubin 10.8 mg/dL. 22 (96%) patients were jaundiced. While all 23 cases 
initially had been suspected of having DILI, 19 were adjudicated as acute HCV and not DILI at 
the 6 month follow-up; while 4 were still considered DILI.
Conclusions: 23 of 1518 (1.5%) cases of suspected DILI were due to acute HCV infection. We 
recommend that initial and follow up HCV RNA testing should be performed to exclude HCV in 
patients with acute hepatocellular injury and suspected DILI.
Keywords
Drug induced liver injury; acute hepatitis C; hepatitis C RNA
Introduction
The diagnosis of drug-induced lived injury (DILI) relies on three main criteria: elevated liver 
biochemistry tests with a compatible history of exposure to a prescription drug or over-the-
counter product, including herbal and dietary supplements (HDS), often with a characteristic 
clinical signature; resolution or improvement upon stopping the agent; and exclusion of 
other causes of liver injury. As there is no specific biomarker of DILI, this last criterion is 
critical, particularly as DILI has a wide spectrum of clinical presentations that can mimic 
viral and autoimmune hepatitis, biliary tract disease, septicemia, ischemic liver injury, and 
malignancy amongst others1.
Chronic hepatitis C virus (HCV) infection affects several million people in the United 
States2, and there has been a recent increase in acute cases likely related to increasing 
injection drug use and the “opiate crisis”3. In addition, outbreaks of acute HCV infection 
continue to be reported after medical and surgical procedures in the health care setting4–6. 
The diagnosis and exclusion of acute and chronic hepatitis C are challenging in patients who 
present with suspected acute DILI. Serological markers for HCV infection, including HCV 
RNA and anti-HCV antibody, are reliable diagnostic markers but have several limitations in 
separating acute from chronic infection. Anti-HCV antibodies are usually used to exclude 
acute hepatitis C in a patient with acute liver injury, but it does not distinguish between 
acute, chronic or resolved hepatitis. Importantly, the absence of anti-HCV antibodies does 
not exclude acute HCV infection, as this antibody may be undetectable early during the 
course of acute infection. Tests for HCV RNA are valuable in distinguishing between active 
and resolved infection, but the presence of HCV RNA does not distinguish between acute 
and chronic hepatitis C, and it may no longer be detectable if tested late during the course of 
acute infection because about 30% of acutely infected patients spontaneously clear HCV and 
cure themselves. There have been approaches to discriminate acute from chronic HCV 
infection using sequence pattern7,8 or antibody avidity9, but none is currently established. 
Thus, reliable diagnosis of acute hepatitis C usually requires testing at two time points 
demonstrating seroconversion to anti-HCV reactivity, de novo development of HCV RNA, 
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or loss of HCV RNA during recovery. These limitations in the diagnostic markers for HCV 
infection are particularly challenging in making a diagnosis of DILI, rather than HCV 
infection.
The Drug-Induced Liver Injury Network (DILIN) is a National Institutes of Health (NIH)-
funded multicenter observational cohort study that prospectively enrolls patients with 
suspected DILI in the United States. Eligible patients must meet predefined laboratory 
criteria and be enrolled within 6 months of DILI onset10. The diagnosis of DILI uses two 
methods: expert consensus and the Roussel Uclaf Causality Assessment Method 
(RUCAM)11,12. Both methods emphasize exclusion of other causes of liver injury, 
particularly viral hepatitis. Formal causality assessment is not undertaken until a 6 month 
follow up visit, and some patients enrolled in DILIN are subsequently determined not to 
have DILI but rather another diagnosis based on follow up testing and history13. The aim of 
the current analysis was to review the results of anti-HCV and HCV RNA testing and their 
diagnostic accuracy in patients enrolled into the DILIN study. Furthermore, after completing 
HCV RNA testing in previously untested patients, we reevaluated patients to determine how 




The DILIN prospective study is a multicenter observational cohort study that enrolls patients 
with suspected DILI. Eligible patients must meet at least one of four predefined laboratory 
criteria on two consecutive blood draws at least 24 hours apart: (1) serum aspartate 
aminotransferase (AST) or alanine aminotransferase (ALT) levels ≥ 5 times the upper limit 
of normal (ULN) or 5 times pretreatment baseline values, if abnormal; (2) serum alkaline 
phosphatase (Alk P) levels that ≥ times the ULN or 2 times the pretreatment value, if 
abnormal; (3) any elevation of ALT, AST or Alk P with a total serum bilirubin of ≥2.5 
mg/dL, or (4) any such enzyme elevations with an international normalized ratio (INR) 
greater than 1.5. Each subject must also be believed to probably have experienced DILI by 
the enrolling hepatologist. Subjects are required to be enrolled within 6 months of onset. 
Patients with acetaminophen hepatotoxicity, liver or bone marrow transplantation, 
autoimmune liver disease, sclerosing cholangitis or decompensated chronic liver disease are 
excluded. Patients with underlying hepatitis B or C, or nonalcoholic and alcoholic fatty liver 
disease are eligible, if the acute injury is believed to be superimposed DILI.
DILIN Study Design:
At the time of enrollment, patients undergo a medical history with details of drug or HDS 
exposure. Medical records are reviewed and data related to the liver injury are retrieved, 
including previous history of liver disease and HCV testing results. Additional laboratory 
testing is performed for other causes of liver injury that were not adequately excluded at the 
time of the initial evaluation. These assessments could include testing for hepatitis A, B, C, 
E, infectious mononucleosis, iron overload, and autoimmune conditions, as well as imaging 
for biliary tract disease10. In the case of hepatitis C, anti-HCV testing was routinely done If 
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not available from the medical records. In contrast, HCV RNA testing was performed at the 
discretion of the principal investigator at each center. In addition, a serum sample is obtained 
at study enrollment, aliquoted and stored at a central DILIN repository. Patients are asked to 
return for a follow-up visit at 6 months after enrollment, and those with persistent evidence 
of liver injury to return again annually for up to 4 years. The DILIN clinical sites and 
investigators are given in Supplementary Table 1.
Causality Assessment:
Enrolled subjects undergo a formal causality assessment process after their 6 month follow 
up visit. To elucidate the most likely cause of liver injury, two methods are employed: a 
consensus opinion by the DILIN Causality Committee made up of experienced hepatologists 
very familiar with DILI anda standardized RUCAM method calculated by the enrolling 
principal investigator. The DILIN causality system employs a 5-point likelihood score: 1 
(definite: ≥ 95% likelihood), 2 (highly likely: 75%-94% likelihood), 3 (probable: 50%-74% 
likelihood), 4 (possible: 25%-49% likelihood) or 5 (unlikely: <25% likelihood); and the 
standardized RUCAM (8). By convention, RUCAM scores are grouped into likelihood levels 
as “excluded” (≤0), “unlikely” (1–2), “possible” (3–5), “probable” (6–8) and “highly 
probable” (≥ 9). In subjects in whom more than 1 agent is implicated, an overall causality 
score is assigned, and separate causality scores are assigned to each suspected drug or HDS.
Injury Assessment:
The pattern of liver injury is categorized using the R-ratio: [ALT/ULN] ÷ [Alk P/ULN], 
hepatocellular being defined by an R ≥ 5, cholestatic ≤ 2 and “mixed” between 2 and 5. A 5-
point scale is used to define severity, ranging from 1 (mild, anicteric), 2 (moderate, 
jaundiced), 3 (moderate and hospitalized), 4 (severe, evidence of hepatic failure), and 5 
(death or liver transplantation due to DILI within 6 months of onset).
HCV Testing:
In patients without locally obtained HCV RNA testing, stored serum samples were retrieved 
from the DILIN Repository and tested at Abbott Laboratories for HCV RNA using Abbott 
RealTime HCV assay (Abbott Molecular, Des Plaines, IL., lower limit of detection 12 IU/
mL). All HCV RNA positive results were repeated for verification, and quantitative HCV 
RNA levels were obtained. Testing at the Abbott Laboratory was performed by persons 
without knowledge of prior HCV RNA or antibody results. Cases positive for anti-HCV 
antibodies or HCV RNA at the Abbott Laboratory were reviewed independently by 4 
experienced hepatologists (JA, JHH, KRR, HLT), and the HCV status was categorized using 
predefined criteria as acute HCV, chronic HCV, resolved HCV, false-positive HCV serology, 
or unknown (Supplemental Material). Furthermore, with inclusion of results of the 
additional testing, the cause of the acute liver injury was re-adjudicated using a consensus 
approach as drug-induced, acute hepatitis C, exacerbation of chronic hepatitis C, or 
unknown. A diagnosis of acute hepatitis C required the presence of HCV RNA and one or 
more of the following: known de novo development of HCV RNA or seroconversion to anti-
HCV, clearance of HCV RNA during follow up (in the absence of antiviral therapy), or 
compatible clinical and virologic course in a person in whom drugs were considered an 
unlikely cause of liver injury.
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Some of the patients included in this analysis have been reported in prior publications from 
the DILIN prospective study1,14. The DILIN prospective study was approved by the 
Institutional Review Boards at each clinical site and data coordinating center and by a 
central Data Safety and Monitoring Board appointed by the NIDDK. All enrolled subjects 
provided written informed consent. The locations and principal investigators of the DILIN 
participating sites are given in the supplementary material.
Results
HCV testing of the total cohort:
Patients with suspected DILI enrolled in the prospective DILIN database between September 
2004 and October 2016 with completed causality assessment and HCV testing results were 
included (Figure 1). Among 1734 patients enrolled, 1518 had undergone 6 months of follow 
up and formal causality adjudication by the time of the data analysis. Initial anti-HCV 
results were available on 1457 (96%) and HCV RNA results on 795 (52%) participants. 
Stored sera were available and selected from 814 subjects (127 of whom already had had 
HCV RNA testing that was repeated) and analyzed for HCV RNA. Thus, in total, HCV 
testing results were available on all 1518 adjudicated patients (1457 for anti-HCV and 1482 
for HCV RNA).
HCV positive cohort:
Of the 1518 participants, 104 (7%) had evidence of current or past HCV infection: 10 were 
positive for HCV RNA alone, 16 for anti-HCV alone, and 78 for both (Figure 2). With the 
addition of these results, all 104 cases were re-reviewed in depth by 4 hepatologists and 
reassessed for causality as well as HCV status using standardized definitions and criteria 
(see above and supplementary material). The 104 cases with at least one positive HCV 
marker were scored by consensus as having acute HCV (n=23), chronic HCV (n=56), or 
resolved HCV (n=13) or as having false positive (n=2) or inconclusive results (n=10). 
Further analysis in this publication was confined to the 23 cases with evidence of acute 
hepatitis C.
Clinical Features of Acute HCV Cases:
The 23 cases of acute HCV infection included 9 women and 14 men, aged 20–83 (mean 47) 
years (Table 1). All presented with acute hepatocellular injury with median ALT 1448 U/L 
(range 458–3501), Alk P 232 U/L (range 92–551), and total bilirubin 10.8 mg/dL (range 
1.1–23.1). The R ratios, calculated on the basis of initial ALT and Alk P values, were all 
above 5 and ranged from 5.3 to 40.7 (median = 18.6). The majority of patients had jaundice 
(96%), and most were hospitalized (78%). The course of disease was considered mild in 1, 
moderate in 20 and severe in 2 (with 1 fatality unrelated to liver disease).
The specific drug initially implicated in causing the liver injury and clinical features of each 
case are shown in Table 2. While all cases initially had been considered to have acute DILI, 
by the time of the original formal adjudication, 6 months later, 19 were judged to be due to 
HCV rather than DILI: At 6 months, 10 had been scored as unlikely [5] and 9 as possible 
[4]. The RUCAM calculated by the primary investigator was very variable but 11 cases 
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scored 6 or higher (probable or highly probable DILI). Only 4 patients had obvious risk 
factors for hepatitis C: 3 with injection drug use and 1 with high-risk sexual behavior. 
Interestingly, 7 patients had undergone an invasive surgical or dental procedure in the 
previous six months. Three patients had HIV co-infection.
The results and timing of the initial anti-HCV antibody and HCV RNA tests of the 23 acute 
HCV patients are shown in Table 3. Anti-HCV antibody was detected in 16 cases (70%) and 
HCV RNA in 22 (94%). The original anti-HCV antibody testing was all performed locally 
and was within a week of onset in 13 (57%), or within the following 2 months in 7 (30%) 
cases. Seven patients initially tested anti-HCV negative, one several weeks before onset 
(case 3); 4 were tested within the first week, and 2 were tested one and two months after 
onset. Four of these 7 were tested for HCV RNA locally and identified as having acute 
hepatitis C. The remaining 3 were not suspected of having HCV infection and were initially 
considered to have DILI, being identified as HCV RNA-positive only by the follow up 
testing at the Abbott Laboratory. A fourth patient, who was believed to have chronic 
hepatitis C with superimposed DILI, was later diagnosed as acute HCV infection based upon 
spontaneous clearance of HCV RNA on a follow up specimen. Thus, lack of HCV RNA 
testing at initial presentation would have missed evidence of HCV infection in 7 patients and 
lack of follow up would have misclassified at least one patient as having chronic rather than 
acute infection. In this cohort, all 23 patients with acute hepatitis C were initially believed to 
have DILI, although 19 were correctly identified once HCV testing was completed locally. 
Four additional patients [4/1518 = 0.26%] were misdiagnosed as having DILI but correctly 
identified once HCV RNA testing was performed on the research serum samples.
Discussion
The accurate diagnosis of DILI remains challenging in the absence of specific biomarkers 
and relies on thorough exclusion of other more common causes of liver injury. Laboratory 
studies in the work-up of DILI should include viral serology for hepatitis A, B and C and 
even hepatitis E in cases presenting with a clinical picture consistent with acute viral 
hepatitis13. It should also include assessment for other etiologies including alcoholic 
hepatitis, autoimmune hepatitis, biliary tract disease and depending on the clinical 
presentation, acute CMV, EBV, and HSV infection, the latter especially in subjects 
presenting with severe or fulminant hepatitis. In this cohort of1518 patients enrolled in the 
DILIN prospective study, 23 (1.5%) cases initially believed by experienced hepatologists to 
be due to DILI were actually due to acute HCV infection. All patients presented with 
hepatocellular injury and often a clinical presentation compatible with DILI. Furthermore, 
most patients did not have an identifiable parenteral risk factor for acute HCV infection, 
although 7 had undergone recent invasive procedures. The causality adjudication process in 
the DILIN is different from clinical practice where management decisions are typically 
made on a real-time basis. The RUCAM score is used to make a diagnosis of DILI but in 
this cohort was not very accurate as 11 of the cases had a RUCAM score of 6 or higher 
suggesting probable or highly probable DILI. This likely reflects that acute hepatocellular 
injury from drugs and hepatitis C have a very similar presentation and the lack of HCV RNA 
in half the cases may have impacted the score as one of the domains of the RUCAM requires 
exclusion of viral hepatitis. To maximize diagnostic accuracy, formal case adjudication in 
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DILIN occurs 6 months or more after enrollment, which allows for thorough testing and 
observance of clinical course. Hence, 19 of the 23 acute HCV cases identified here were not 
adjudicated as DILI when reviewed 6 months after onset. Nevertheless, analysis of archived 
serum samples revealed that 4 cases initially adjudicated as DILI after at least 6 months of 
follow up in fact had experienced acute HCV infection. Three of these cases were anti-HCV 
negative on study entry but had not been tested for HCV RNA locally and were found to be 
positive after testing of stored samples. A fourth case was belatedly diagnosed as acute 
hepatitis C based upon spontaneous clearance of HCV RNA detected at follow up. All 23 
cases presented as acute hepatocellular injury compatible with acute viral hepatitis. The 
reason why drugs instead of HCV were initially considered the cause of liver injury was 
usually because of the lack of identifiable risk factors or the suspicion that positive HCV 
antibodies represented chronic HCV infection.
These data demonstrate that anti-HCV antibody testing is used in most centers to exclude 
HCV as a cause of acute hepatitis as it was tested in almost all patients. In contrast, testing 
for HCV RNA was done in only half of cases. The initial testing was done largely by the 
local physicians who referred cases to the DILIN investigators. Some patients were known 
to have chronic HCV before enrollment and were thought to have superimposed DILI. In 
others, the diagnosis of hepatitis C was not considered and testing for anti-HCV was not 
done until enrollment into DILIN, which might occur weeks or months after onset. 
Similarly, HCV RNA testing was occasionally delayed for several weeks or months after the 
suspected DILI onset. Such variability reflects the variability of HCV testing in clinical 
practice and evaluation of potential DILI.
In the entire DILIN prospective cohort1, just over half of patients presented with acute 
hepatocellular injury, and about two thirds had jaundice. Not surprisingly, in these 23 acute 
HCV cases, all had hepatocellular injury and almost all had jaundice, but the other 
demographic factors such as age, sex, and race were similar to most patients that are 
enrolled as were the types of putative suspect drugs with antimicrobials accounting for 10 
cases. The agents implicated initially in these 23 cases included many well-known causes of 
DILI, but often the phenotype of the injury was atypical, for example markedly 
hepatocellular injury after amoxicillin/clavulanate, intense jaundice and a long latency 
period and no immunoallergic features after fluoroquinolones. Other cases appeared to 
implicate agents that are after niacin, known but very rare causes of liver injury, such as 
escitalopram, naproxen, carboplatin, glipizide, and linezolid.
The limitations of this study deserve mention. HCV RNA testing was not available in all 
patients, and the local assays used to test for anti-HCV and HCV RNA were not uniform or 
applied from the same time points after onset. For instance, in one case (#23), HCV RNA 
was negative when tested locally but was repeatedly positive (in low titer) when rechecked 
centrally. In addition, some patients lacked testing at the appropriate times as in case #15 
where the HCV RNA was drawn 7 weeks before DILI onset and case #8 where it was tested 
24 weeks after onset. Other cases lacked any HCV RNA testing such that it was impossible 
to assign a confident diagnosis. Most patients did not have definitive evidence of acute HCV 
(documented negative serology before liver injury and evidence of seroconversion or 
development of HCV RNA). Nevertheless, only cases that fit strict consensus criteria for 
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acute HCV infection were included, so that the overall rate was, if anything, an 
underestimate. Among the 104 patients with positive HCV serology, results from 10 were 
considered inconclusive because the available results could not distinguish acute from 
chronic infection. Among the 23 patients diagnosed as having acute infection, only 11 had 
follow up testing from 6 months or more after onset, in whom with spontaneous clearance 
occurred in 6, while the remaining 5 appeared to go on to develop chronic hepatitis, 2 of 
who then underwent successful anti-viral treatment.
In conclusion, 23 (1.5%) patients believe by experienced hepatologists to have DILI had 
acute HCV infection that was diagnosed during follow-up. These patients all presented with 
hepatocellular injury, the majority had jaundice and most had no known risk factors for HCV 
infection. The diagnosis was only reliably made based upon HCV RNA testing which was 
positive in 7 subjects while they were anti-HCV negative at the time of their initial testing. 
These findings indicate that patients presenting with acute hepatocellular injury, even with 
features suggestive of DILI, should be tested for both anti-HCV and HCV RNA to reliably 
exclude acute HCV infection. Establishing the diagnosis of acute hepatitis C and careful 
follow up is all the more important now that safe and highly effective therapies are available 
for HCV infection.
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Alk P Alkaline phosphatase
AST Aspartate aminotransferase
DILI Drug induced liver injury
DILIN Drug Induced Liver Injury Network
HCV Hepatitis C virus
INR International normalized ratio
ULN Upper limit of normal
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Flowchart of 1734 subjects enrolled in DILIN prospective study with HCV testing
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Breakdown of 104 subjects in DILIN prospective study with positive HCV testing
Ahmad et al. Page 12

























Ahmad et al. Page 13
Table 1
Clinical Features of 23 patients with acute hepatitis C
Feature Units Value or Number Range or Percent
Median Age Years 46 20 to 83
Male Sex 14 61%
White Race 21 91%
Median initial ALT U/L 1448 458 to 3501
Median initial Alk P U/L 232 92 to 551
Median initial total bilirubin mg/dL 10.8 1.1 to 23.1
Bilirubin ≥ 2.5 mg/dL 22 96%
Median initial R ratio 18.6 5.3 to 40.7
Severity score
 Mild (1+) 1 4%
 Moderate (2+) 4 17%
 Moderate-hospitalized (3+) 16 70%
 Severe (4+) 2 9%
Risk factor for HCV acquisition 4 23%
Anti-HCV negative initially 7 35%
HCV RNA done initially 19 83%
HCV RNA done in follow up at 6 months 11 48%
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Table 3
Timing of HCV Testing in 23 Acute HCV Cases in DILIN Prospective Study
Case Anti-HCV result Days from onset to anti-
HCV test
HCVRNA result HCV RNA titer [Log 
IU/mL]
Days from onset to HCV 
RNA test
1 Positive 0 Positive 1.87 7
2 Negative 0 Positive 3.22 8
3 Negative −49 Positive 6.06 6
4* Positive 19 Positive 5.54 0
5 Positive 5 Positive 5.41 5
6 Positive 91 Positive 7.05 91
7 Negative 31 Positive NA 10
8 Positive 189 Positive NA 2
9 Positive 33 Positive 4.74 19
10* Negative 0 Positive 7.19 24
11 Positive 3 Positive 1.62 11
12 Positive 0 Positive 6.27 0
13 Positive 24 Positive 3.09 24
14 Positive 0 Positive 4.54 1
15 Positive 1 Negative NA −49
16 Positive 0 Positive 5.71 4
17 Negative 46 Positive 6.65 69
18 Positive 1 Positive 1.73 12
19* Negative 0 Positive 5.66 7
20 Positive 14 Positive 6.58 23
21* Negative 0 Positive 2.76 11
22 Positive 6 Positive NA 9
23** Positive 49 Positive 2.24 105
*
HCV RNA not checked locally but stored serum was positive
**
HCV RNA negative when checked locally at 105 days after DILI onset but stored sera from same time was positive when retested
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